Nucleoside analogues and patterns of salivary, pancreatic and total amylase in HIV positive individuals.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Nucleoside analogues and patterns of salivary, pancreatic and total amylase in HIV positive individuals.

Int Conf AIDS. 1992 Jul 19-24;8(1):Mo21 (abstract no. MoB 0078). Unique Identifier : AIDSLINE ICA8/92400037
Sweeney JN; Valentine CB; Gompells M; Pinching AJ; Sherwood R; Deenmamode J; Moncrieff KC; Aber VR; St Mary's Hospital, London, UK.

Abstract: OBJECTIVES: To assay total, salivary and pancreatic amylase in a group of HIV positive patients attending St Mary's Hospital London to determine whether stage of HIV infection or administration of nucleoside analogues affects serum amylase concentrations. METHODS: Stored serum from 102 HIV positive patients attending St Mary's Hospital were measured. Four groups were identified: Asymptomatic/ARC on zidovudine (AZT), or on no nucleoside analogues, AIDS on didanosine (ddI), or on no nucleoside analogues. The results were analysed using analysis of variance with BMDP statistical software. RESULTS: TABULAR DATA, SEE ABSTRACT VOLUME. There was a highly significant difference in total serum amylase in patients taking ddI and patients not taking ddI. (P = 0.005 by ANOVAR.) This effect was not attributable to stage of HIV infection. It is not clear whether this represents an abnormality of salivary or pancreatic amylase and suggests heterogeneity in the source of elevated amylase in patients taking ddI. Some patients had markedly abnormal serum amylase values. These patients did not have symptoms to suggest a cause for this biochemical abnormality. CONCLUSIONS: Total serum amylase was elevated in those patients taking ddI. There was not a consistent pattern of salivary or pancreatic abnormality suggesting differing underlying mechanisms.

Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY/ENZYMOLOGY Amylases/*BLOOD/CLASSIFICATION AIDS-Related Complex/DRUG THERAPY/ENZYMOLOGY Comparative Study Didanosine/PHARMACOLOGY/*THERAPEUTIC USE Human HIV Seropositivity/*DRUG THERAPY/ENZYMOLOGY Pancreas/ENZYMOLOGY Saliva/ENZYMOLOGY Zidovudine/PHARMACOLOGY/*THERAPEUTIC USE ABSTRACT
921230
M92C5310

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .